Sentynl Therapeutics’ Acquisition of Cyprium Therapeutics

Pillsbury Winthrop Shaw Pittman LLP advised Sentynl Therapeutics on the deal.

Sentynl Therapeutics, a USA-based specialty pharma company owned by the India’s Zydus Group, announced the agreement to acquire Cyprium Therapeutics’ proprietary rights to CUTX-101, its copper histidinate product candidate for the treatment of Menkes disease.

Sentynl will acquire CUTX-101 for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties.

Cyprium will retain development responsibility of CUTX-101 through approval of the NDA and the U.S. FDA. Sentynl will be responsible for commercialization of CUTX-101 as well as progressing newborn screening activities. Continued development of CUTX-101 will be overseen by a Joint Steering Committee consisting of representatives from Cyprium and Sentynl.

The Pillsbury team included Christian Salaman (Picture) and Mustapha Parekh.

Involved fees earner: Mustapha Parekh – Pillsbury Winthrop Shaw Pittman LLP; Christian Salaman – Pillsbury Winthrop Shaw Pittman LLP;

Law Firms: Pillsbury Winthrop Shaw Pittman LLP;

Clients: Sentynl Therapeutics;

Author: Martina Bellini